anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cystic fibrosis (CF) affects about 30,000 people in the United States. It is caused by an absent or dysfunctional protein called CF transmembrane conductance regulator (CFTR) which functions as a chloride channel. Lubiprostone is a medication indicated for constipation that activates type 2 chloride channels (ClC-2) and has the potential to be an effective treatment for constipation in adults with CF. It has the potential to correct the underlying disorder by utilizing a chloride channel whose activity does not depend on CFTR. This project is a prospective open-label pilot study to examine the safety and effectiveness of lubiprostone when used in adults with CF with constipation. The specific aims are as follows: 1) Determine the effectiveness of lubiprostone for constipation in participants with CF, and 2) Determine the short term safety of lubiprostone in adults with CF. Data will also be collected to generate further information about the effect of lubiprostone on nutritional status.
A method of producing rat monoclonal antibodies to human T-cell lymphocyte antigen epitopes other than those epitopes defined by murine monoclonal antibodies directed to the same antigen comprising: (1) immunizing a rat or rat immunocompetent cells  in vitro  with an immunogenic amount of an antigen comprising T-cell lymphocyte markers; (2) fusing immunized cells from said rat or immunized rat immunocompetent cells with immunocytoma cells; (3) selecting hybridoma cells that produce antibody that binds to the human T-cell lymphocyte antigen epitopes other than those epitopes defined by murine monoclonal antibodies directed to the same antigen; (4) culturing the selected hybridoma cells; and (5) recovering said antibody. A method of producing rat monoclonal antibodies that bind to human CD4 antigen, the method comprising: (1) immunizing a rat or rat immunocompetent cells  in vitro  with an immunogenic amount of an antigen comprising CD4 molecule; (2) fusing immunized cells from said rat or immunized rat immunocompetent cells with immunocytoma cells; (3) selecting hybridoma cells that produce antibody that binds to human CD4 antigen; (4) culturing the selected hybridoma cells; and (5) recovering said antibody. A hybridoma that produces a rat monoclonal antibody that binds to human CD4 antigen. A rat monoclonal antibody that binds to human CD4 antigen.   In a preferred embodiment the rat monoclonal antibody binds to a human CD4 antigen epitope other than those epitopes defined by murine monoclonal antibodies OKT4 and Leu3a. A rat monoclonal antibody that binds to human T-cell lymphocyte antigen epitopes other than those epitopes defined by murine monoclonal antibodies directed to the same antigen.
Inflammatory skin conditions highly influence the quality of life of the patients suffering from these disorders. Symptoms include red, itchy and painful skin lesions, which are visible to the rest of the world, causing stigmatization and a significantly lower mental health of the patients. Treatment options are often unsatisfactory, as they suffer from either low patient adherence or the risk of severe side effects. Considering this, there is a need for new treatments, and notably of new ways of delivering the drugs. Stimuli-responsive drug delivery systems are able to deliver their drug cargo in response to a given stimulus and are, thus, promising for the treatment of inflammatory skin conditions. For example, the use of external stimuli such as ultraviolet light, near infrared radiation, or alteration of magnetic field enables drug release to be precisely controlled in space and time. On the other hand, internal stimuli induced by the pathological condition, including pH alteration in the skin or upregulation of reactive oxygen species or enzymes, can be utilized to create drug delivery systems that specifically target the diseased skin to achieve a better efficacy and safety. In the latter context, however, it is of key importance to match the trigger mechanism of the drug delivery system to the actual pathological features of the specific skin condition. Hence, the focus of this article is placed not only on reviewing stimuli-responsive drug delivery systems developed to treat specific inflammatory skin conditions, but also on critically evaluating their efficacy in the context of specific skin diseases. STATEMENT OF SIGNIFICANCE: Skin diseases affect one-third of the world's population, significantly lowering the quality of life of the patients, who deal with symptoms such as painful and itchy skin lesions, as well as stigmatization due to the visibility of their symptoms. Current treatments for inflammatory skin conditions are often hampered by low patient adherence or serious drug side effects. Therefore, more emphasis should be placed on developing innovative formulations that provide better efficacy and safety for patients. Stimuli-responsive drug delivery systems hold considerable promise in this regard, as they can deliver their cargo precisely where and when it is needed, reducing adverse effects and potentially offering better treatment outcomes.
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Smilax scobinicaulis C.H. Wright esophagus cancer treatment granule. The granule is a green high-tech Chinese herbal medicine used for treating the esophagus cancer. The granule is a traditional Chinese medicinal granule prepared through the following steps: mixing of Smilax scobinicaulis C.H. Wright, Rhizoma Curcumae, dry root of Stephania tetrandra S., sal ammoniac and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction, concentration and granulation. The granule is mainly used for treating the esophagus cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The granule has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The granule fundamentally improves the body functions and prevents cancer cancerization at a low cost in order to recover the health of bodies.
The invention provides new application of stilbene glucoside to hangover alleviation. The stilbene glucoside has the functions of alleviating hangover and protecting liver, and inducing resuscitation and benefiting intelligence, and has the effect of preventing and treating alcoholic liver, fatty liver, liver injury, cerebral injury, memory deterioration and the like which are all caused by long term or quantity of alcohol drinking. The stilbene glucoside can be applied to hangover-alleviating medicaments. The stilbene glucoside and pharmaceutically acceptable salts, esters or sugars thereof are used for preparing the hangover-alleviating medicaments. The stilbene glucoside and the pharmaceutically acceptable salts, esters or sugars thereof can be prepared into pharmaceutically acceptable formulations, such as tablets, capsules, solutions, injections, granules, drips, micro pills and the like. The stilbene glucoside has wide application prospect in aspects of medical healthcare and the like.
PURPOSE: This meta-analysis compared the efficacy and safety of Proximal Femoral Nail Antirotation (PFNA) and InterTan Nail in the treatment of intertrochanteric fractures. Given the high incidence of femoral intertrochanteric fractures in the elderly population and its impact on quality of life, choosing the most effective and safest surgical option is crucial. PFNA and InterTan are currently two commonly used techniques, but there is a lack of systematic evaluation comparing their safety and effectiveness. This study aims to fill this knowledge gap through Meta-analysis, providing clinicians with evidence-based treatment recommendations.
MATERIALS AND METHODS: A computer search was used to search for published literature on PFNA and InterTan in the treatment of intertrochanteric fractures in PubMed (Medline), Web of Science, Embase, Cochrane Library (CENTRAL), Cinahl, CBM, and CNKI.A total of 853 related literatures were retrieved, and 15 literatures were finally included. Newcastle-Ottawa-Scale and Cochrane systematic review methodologies were used to assess the quality of the literature. Meta-analysis was performed using Review Manager 5.4 software, following data extraction.
RESULTS: The comparison found that during the surgical treatment of intertrochanteric fractures, the operation time, fluoroscopy time, and blood loss in the PFNA group were significantly shorter than those in the InterTan group, and the difference was statistically significant. In terms of postoperative complication rates, the InterTan group had a significant advantage over the PFNA group. Shaft fracture, varus collapse, cut out, screw migration, and pain of hip and thigh were the most likely to occur in the PFNA group, and the differences were all statistically significant. In terms of postoperative efficacy, the results of the PFNA group and the InterTan group were comparable, and there was no significant differences.
CONCLUSIONS: When selecting surgical techniques for the treatment of femoral intertrochanteric fractures, it is necessary to conduct individualized assessments based on the patient's overall health status, surgical tolerance, and post-operative recovery needs. For patients who cannot tolerate long-term surgery or are in poor physical condition, PFNA may be more appropriate. While for patients who can tolerate long-term surgery or have more complex conditions, InterTan may be more suitable.
PURPOSE:To produce the titled complex having a high purity, by subjecting a blood-coagulating factor IX-contg. soln. contaminated with an antigen relating to blood-coagulating factor VIII to a salting-out treatment using ammonium sulfate. CONSTITUTION:A blood-coagulating factor IX-contg. soln. which may be contaminated with an antigen relating to blood-coagulating factor VIII is treated with 5-45%, preferably 15-35% ammonium sulfate at 5-9pH, preferably 6-8pH at <=15 deg.C, preferably 2-10 deg.C to precipitate the antigen relating to the factor VIII. The treated soln. is e.g. centrifuged to recover the supernatant, which is optionally dialysed or otherwise treated to separate the salt to provide the highly pure factor IX or a complex thereof.
Preservative-free TIMOPTIC in OCUDOSE is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be guaranteed after the individual unit is opened, the remaining contents should be discarded immediately after administration.

Preservative-free TIMOPTIC in OCUDOSE is available in concentrations of 0.25 and 0.5%. The usual starting dose is one drop of 0.25% Preservative-free TIMOPTIC in OCUDOSE in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) administered twice a day.

Since in some patients the pressure-lowering response to Preservative-free TIMOPTIC in OCUDOSE may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Preservative-free TIMOPTIC in OCUDOSE.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Dosages above one drop of 0.5% TIMOPTIC (timolol maleate ophthalmic solution) twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives. The concomitant use of two topical beta-adrenergic blocking agents is not recommended (see PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents).
This case highlights a rare presentation of diverticulitis of the sigmoid colon with perforation into the retroperitoneum complicated by abscess, vertebral osteomyelitis and acute lower extremity ischemia. A late 40-year-old man presented to an emergency department with acute ischemia of his left lower extremity. He was tachycardic with a leucocytosis, an unremarkable abdominal exam and a pulseless, insensate and paralysed left lower extremity. Imaging revealed sigmoid thickening, an abscess adjacent to iliac vasculature and occlusion of the left popliteal artery. The abscess came in contact with prior spine anterior lumbar interbody fusion (ALIF) hardware at L5-S1 vertebrae. The patient was taken urgently to the operating room for embolectomy, thrombectomy and fasciotomy. He was started on antibiotics and later underwent operative drainage with debridement for osteomyelitis. Non-operative management of the complicated diverticulitis failed, necessitating open sigmoidectomy with colostomy. 1 year later, he was symptom-free and the colostomy was reversed.
Asthma is a chronic disease that is estimated to affect over 25 million people both in the U.S. and in Europe (i.e. approximately 10% of the total population). Pharmacological therapy is used to treat reversible airway obstruction, inflammation and hyper-reactivity. Medications include preventive treatments in forms of antinflammatory/antiallergic agents (i.e. glucocorticosteroids, leukotriene antagonists, cromolyn sodium) and reliever treatments, in forms of bronchodilators (i.e. β-adrenergic agonists, anticholinergics). In patients treated with inhaled glucocorticosteroids whose asthma is not fully controlled, national and international guidelines recommend a stepwise approach. Recent evidence-based clinical trials show that the addition of a LABA to inhaled glucocorticosteroids is more beneficial in terms of asthma control than increasing the dose of corticosteroids alone.

COMPARISONS: CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg+ FORMOTEROL 6 µg) pMDI via HFA-134a compared to SYMBICORT (BUDESONIDE 160 µg + FORMOTEROL 4,5 µg).
The invention comprises compounds having the formula <FORM:1075300/C2/1> wherein R1 is a hydrogen atom or a C1- 6 alkyl group, R2 is furylmethylamino, thenylamino, benzylamino or dibenzylamino and carboxylic acid salts thereof.  The novel compounds may be made by nitrating a 2-halo-4-trifluoromethylbenzoic acid to give a 2-halo-5-nitro-4-trifluoromethylbenzoic acid, reducing this to a 5-amino-2 - halo - 4 - trifluoromethylbenzoic acid, treating this product with conc. HCl and sodium nitrite followed by SO2 in acetic acid containing cuprous chloride, treating the resulting 4-chlorosulphonyl compound with ammonium hydroxide or an alkylamine to give a 2-halo-5 - sulphamoyl - 4 - trifluoromethyl benzoic acid and reacting this with R2H to give the desired product. Alternatively, a 2-bromo-5-trifluoromethylanilin is converted to 4-trifluoromethylanthranilonitrile. This benzonitrile may be reacted with chlorosulphonic acid and ammonium hydroxide or alkylamine to give 5 - sulphamoyl - 4 - trifluoromethylanthranilonitrile which is hydrolysed to the corresponding anthranilic acid.  Alternatively, the benzonitrile may be hydrolysed first and then sulphamoylated.  The 5-sulphamoyl-4-trifluoromethylanthranilic acid is reacted with RCHO in which R is phenyl, furyl or thienyl and the resulting Schiff base is reduced to give the desired N - substituted - 5 - sulphamoyl -4 -trifluoromethylanthranilic acid.ALSO:Pharmaceutical compositions having diuretic activity comprise a pharmaceutical carrier in association with an N-substituted-5-sulphamoyl - 4 - trifluoromethylanthranilic acid of the formula: <FORM:1075300/A5-A6/1> where R1 is hydrogen or alkyl having 1 to 6 carbon atoms and R2 is furylmethylamino thenylamino, benzylamino or dibenzlamino, or a carboxylic acid salt thereof, with or without a 2,4,7-triamino-6-phenyl pteridine of the formula: <FORM:1075300/A5-A6/2> where R3 is hydrogen or alkyl having 1 to 3 carbon atoms and R4 is hydrogen, alkyl having 1 to 3 carbon atoms, trifluoromethyl, halo or alkoxy having 1 to 3 carbon atoms.  With a solid carrier, the composition may be in the form of tablets, hard gelatin capsules, troches or lozenges.  With a liquid carrier, the composition may be in the form of a soft gelatin capule or a liquid suspension.  The compositions may be administered orally or parentally
Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
A woman in her forties visited an ophthalmologist for rapidly progressive foggy vision. Naked visual acuity had decreased to 0.15, and although her eyes showed no abnormalities, internal disease was suspected and albumin 2.6 g/dL was found. Protein leakage from the intestinal tract was suspected since there was no urinary protein excretion. 99mTechnetium-labeled albumin D scintigraphy showed protein leakage from the intestinal tract. A stool α1-antitrypsin clearance test showed an increase to 56.3 mL/day, leading to a diagnosis of protein-losing gastroenteropathy. Blood biochemistry revealed abnormally high levels of anti-SS-A and anti-SS-B antibodies (≥ 1200 U/mL and ≥ 1000 U/mL, respectively). A lip salivary gland biopsy revealed lymphocytic infiltrate at least 1 focus per 2 mm × 2 mm > 50 lymphocytes per conduit). The Schirmer test result was 5 mm/5 min or less, which led to the diagnosis of Sjögren's syndrome. The serum albumin level increased with intravenous administration of methylprednisolone 50 mg (1 mg/kg), and the patient is currently on oral prednisolone at a gradually decreasing dose. After administration of prednisolone, visual acuity recovered to 1.2 with recovery of albumin.
PCT No. PCT/JP96/00842 Sec. 371 Date Apr. 16, 1997 Sec. 102(e) Date Apr. 16, 1997 PCT Filed Mar. 10, 1996 PCT Pub. No. WO96/29975 PCT Pub. Date Oct. 3, 1996An oil-water mixed composition is consisted of a solid or semisolid oil phase at room temperature, and a water phase which is dispersed into the oil phase. The water phase contains a humectant and is solid or semisolid at room temperature. Preferably, the oil phase contains hydrophobic silica, dextrin fatty acid ester or polyvalent alcohol oligo ester of long chain monocarboxylic acid and long chain dicarboxylic acid. The oil-water mixed composition is superior in stability with passage of time and safety. In addition, this composition has demonstrated little stickiness and sensation of unsuitability for skin, and has much emollient effect (i.e., to prevent the skin from dryness) and is persistent in preserving its emollient effect.
Embolization is the standard of care for pulmonary arteriovenous malformations (PAVMs) in the Hereditary Hemorrhagic Telangiectasia (HHT) population. PAVMs are abnormal connections between the veins and arteries and result in right-to-left shunting of blood within the lungs. Successful embolization results in PAVM resolution and decreases the complications associated with right-to-left shunting. Current guidelines recommend follow-up with interval chest CT scan to determine treatment success and detect new or recurrent PAVMs after embolization. This results in significant radiation exposure to the relatively young HHT population. An alternative to chest CT is graded transthoracic contrast echocardiography (TTCE), which measures the amount of right-to-left shunting within the lung and assigns a grade based on this amount. TTCE has the advantage of being radiation free compared to chest CT. To date, graded TTCE has only been studied as a screening tool for PAVMs. These studies have shown that graded TTCE is highly sensitive in detecting PAVMs and is comparable to chest CT when screening for PAVMs. Results indicate that TTCE grade can accurately predict PAVM size on chest CT and predict whether PAVMs are amenable to embolization. However, no studies have compared graded TTCE and chest CT in patients who are post-embolization and it is therefore unknown whether graded TTCE can be used in patients who have undergone PAVM embolization. The current study seeks to correlate post-embolization TTCE grade with chest CT findings to determine whether TTCE can accurately predict PAVM size and amenability to treatment in the post-embolization population.
An anti cavity bioconsumable liquid which may be provided in the liquid form or frozen form is disclosed herein. The liquid may include up to about 5 wt. % xylitol for the purposes of mitigating tooth decay when the bioconsumable liquid is ingested or consumed by a person. Moreover, the bioconsumable liquid may include up to about 5 wt. % of dextrose but never more than the wt. % of xylitol for the purposes of sweetening the bioconsumable liquid to retain an acceptable flavor profile. An infant, child or adult may consume the bioconsumable liquid during which the xylitol acts to mitigate tooth decay. The bioconsumable liquid may also be frozen in an ice pop configuration and consumed by a child or an adult. The ice pop retains an acceptable flavor profile and also mitigates tooth decay.
The safety and efficacy of another somatropin product in the treatment of children born small for gestational age (SGA) were evaluated in 4 randomized, open-label, controlled clinical trials. Patients (age range of 2 to 8 years) were observed for 12 months before being randomized to receive either this other somatropin product (two doses per study, most often 0.24 and 0.48 mg/kg/week) as a daily SC injection or no treatment for the first 24 months of the studies. After 24 months in the studies, all patients received this other somatropin product.

Patients who received any dose of this other somatropin product showed significant increases in growth during the first 24 months of study, compared with patients who received no treatment (see Table 8). Children receiving 0.48 mg/kg/week demonstrated a significant improvement in height standard deviation score (SDS) compared with children treated with 0.24 mg/kg/week. Both of these doses resulted in a slower but constant increase in growth between months 24 to 72 (data not shown).